Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.38% $2.86
America/New_York / 28 mar 2024 @ 10:05
FUNDAMENTALS | |
---|---|
MarketCap: | 23.19 mill |
EPS: | -4.18 |
P/E: | -0.680 |
Earnings Date: | Apr 30, 2024 |
SharesOutstanding: | 8.11 mill |
Avg Daily Volume: | 0.0233 mill |
RATING 2024-03-27 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.680 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.12x |
Company: PE -0.680 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.73 - 2.99 ( +/- 4.51%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Pitukcheewanont Pisit Duke | Sell | 0 | Common Stock |
2023-06-01 | Pitukcheewanont Pisit Duke | Sell | 29 750 | Stock Option (Right to Buy) |
2024-02-01 | Pitukcheewanont Pisit Duke | Sell | 3 333 | Stock Option (Right to Buy) |
2024-07-01 | Pitukcheewanont Pisit Duke | Sell | 25 500 | Stock Option (Right to Buy) |
2023-08-01 | Mckew John C. | Sell | 1 593 | Common Stock |
INSIDER POWER |
---|
23.92 |
Last 99 transactions |
Buy: 596 623 | Sell: 145 033 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.86 (-1.38% ) |
Volume | 0.0002 mill |
Avg. Vol. | 0.0233 mill |
% of Avg. Vol | 0.876 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.